A citation-based method for searching scientific literature

Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
Times Cited: 212



David Fitchett, Javed Butler, Philippe van de Borne, Bernard Zinman, John M Lachin, Christoph Wanner, Hans J Woerle, Stefan Hantel, Jyothis T George, Odd Erik Johansen, Silvio E Inzucchi. Eur Heart J 2018
Times Cited: 145




List of shared articles



Times cited

Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Xiao-Dong Zheng, Qiang Qu, Xing-Yu Jiang, Zhong-Yuan Wang, Cheng Tang, Jin-Yu Sun. Am J Cardiovasc Drugs 2021
2

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
5

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.
Roy Rasalam, John J Atherton, Gary Deed, Michael Molloy-Bland, Neale Cohen, Andrew Sindone. ESC Heart Fail 2021
1

CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.
Gianluigi Savarese, Javed Butler, Lars H Lund, Deepak L Bhatt, Stefan D Anker. Cardiovasc Res 2021
0

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0

Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?
Xian-Pei Heng, Xiu-Jun Li, Liang Li, Liu-Qing Yang, Zi-Ta Wang, Su-Ping Huang. Chin J Integr Med 2020
1

Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S Aronow, William H Frishman. Cardiol Rev 2020
3

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
Dulce Brito, Paulo Bettencourt, Davide Carvalho, Jorge Ferreira, Ricardo Fontes-Carvalho, Fátima Franco, Brenda Moura, José Carlos Silva-Cardoso, Rachel Tavares de Melo, Cândida Fonseca. Cardiovasc Drugs Ther 2020
4

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Kamlesh Khunti, David H Fitchett, Christoph Wanner, Michaela Mattheus, Jyothis T George, Anne Pernille Ofstad, Bernard Zinman. J Clin Endocrinol Metab 2020
5